LY-411575: Potent γ-Secretase Inhibitor for Amyloid Beta and Notch Pathway Modulation

Executive Summary: LY-411575 is a potent and selective inhibitor of γ-secretase, exhibiting an IC50 of 0.078 nM in membrane-based assays and 0.082 nM in cell-based assays for γ-secretase inhibition (APExBIO). It reduces amyloid beta (Aβ40 and Aβ42) production and blocks Notch S3 cleavage with an IC50 of 0.39 nM, modulating pathways involved in Alzheimer's disease and oncogenesis (Satir et al. 2020). In vivo, oral dosing (1–10 mg/kg) in CRND8 mice decreases brain and plasma Aβ levels. The compound is insoluble in water but highly soluble in DMSO (≥23.85 mg/mL). LY-411575 is formulated for preclinical research and provided by APExBIO as SKU A4019.

Biological Rationale

Alzheimer's disease (AD) is characterized by extracellular deposition of amyloid beta (Aβ) peptides, especially Aβ42, which aggregate into plaques and are implicated in neurotoxicity and disease progression (Satir et al. 2020). Aβ peptides are generated by sequential cleavage of amyloid precursor protein (APP), first by β-secretase (BACE), then by γ-secretase, an intramembrane aspartyl protease complex. γ-Secretase also cleaves Notch receptors, thus modulating the Notch signaling pathway, central to cell fate, proliferation, and apoptosis. Dysregulation of these pathways is implicated in neurodegeneration and various cancers, including leukemia and Kaposi's sarcoma (APExBIO).

Mechanism of Action of LY-411575

LY-411575 binds the active site of presenilin, the catalytic subunit of γ-secretase. This binding blocks the intramembrane cleavage of type-I membrane proteins, including APP and Notch receptors. Inhibition of γ-secretase suppresses production of Aβ40 and Aβ42, reducing amyloidogenic burden. Simultaneously, LY-411575 inhibits Notch S3 cleavage, thereby disrupting downstream Notch signaling and inducing apoptosis in tumor cells (Related Article). The compound demonstrates high selectivity, with negligible activity against other proteases at research concentrations.

Evidence & Benchmarks

• LY-411575 inhibits γ-secretase in membrane-based assays with an IC50 of 0.078 nM, demonstrating high potency (APExBIO).
• In cell-based assays, the IC50 for γ-secretase inhibition is 0.082 nM, confirming efficacy in cellular contexts (APExBIO).
• Notch S3 cleavage is inhibited with an IC50 of 0.39 nM, supporting Notch pathway modulation (Related Article).
• Oral administration at 1–10 mg/kg in CRND8 transgenic mice significantly reduces brain and plasma Aβ levels in vivo (APExBIO).
• γ-Secretase inhibition can decrease Aβ production up to 50% without impairing synaptic transmission, as shown for related secretase inhibitors (Satir et al. 2020).

This article extends prior reviews such as 'LY-411575: Mechanistic Precision and Strategic Horizons' by providing atomic, quantitative performance metrics and workflow parameters relevant to experimental design, and clarifies solubility/storage details not covered elsewhere.

Applications, Limits & Misconceptions

LY-411575 is used in preclinical Alzheimer's disease models to reduce Aβ production and as a research tool to modulate Notch signaling in cancer studies (Related Article). Its high selectivity for γ-secretase enables precise interrogation of intramembrane aspartyl protease functions. The compound is also instrumental in apoptosis induction studies via Notch inhibition.

Common Pitfalls or Misconceptions

• LY-411575 is not suitable for clinical use; it is strictly for laboratory research (APExBIO).
• It is insoluble in water; attempts to dissolve in aqueous buffers will fail (APExBIO).
• Long-term storage of solutions is not recommended; degradation may occur, reducing efficacy (APExBIO).
• γ-Secretase inhibition can affect multiple substrates, potentially leading to off-target effects if not carefully controlled (Satir et al. 2020).
• Unlike BACE inhibitors, γ-secretase inhibitors have failed in clinical trials due to side effects arising from broad substrate inhibition (Satir et al. 2020).

Workflow Integration & Parameters

LY-411575 is typically prepared as a 10 mM stock solution in DMSO. Solubility is ≥23.85 mg/mL in DMSO and ≥98.4 mg/mL in ethanol (with ultrasonic treatment). Stock solutions should be warmed or sonicated to enhance dissolution. For animal dosing, the compound is formulated in a vehicle containing polyethylene glycol, propylene glycol, ethanol, and methylcellulose. Storage is recommended at -20°C as a solid; solutions should be used promptly and are not intended for long-term storage (APExBIO).

This article updates and clarifies guidance over 'LY-411575: Strategic γ-Secretase Inhibition for Translational Research' by providing explicit workflow parameters and storage best practices to maximize compound integrity.

Conclusion & Outlook

LY-411575, as provided by APExBIO, is a potent, selective tool for investigating γ-secretase and Notch pathway biology. Its low nanomolar IC50 values in both membrane and cell-based systems, robust in vivo efficacy, and well-characterized solubility/storage properties make it indispensable for Alzheimer's and cancer research. While clinical translation has been limited by on-target and off-target effects, LY-411575 remains a gold-standard reference compound for mechanistic and translational studies. For further mechanistic insight and comparative data, see 'LY-411575: Transforming Translational Research with Precision', which this article complements by providing expanded workflow recommendations and a detailed evidence audit.

For procurement and complete technical details, consult the product page for LY-411575 (A4019).